In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
UK-based Mogrify, a regenerative medicine company developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need, has announced the appointment of Jonathan Appleby as chief scientific officer (CSO). 15 July 2024
Pharmaceutical
The wait for Eli Lilly's Mounjaro (tirzepatide) has got longer in India. 15 July 2024
Pharmaceutical
The number of diagnosed chronic kidney disease (CKD) cases in seven major markets is expected to rise from around 21 million to 23 million by 2033. 15 July 2024
Pharmaceutical
Spanish drugmaker PharmaMar has received a notification from the European Commission (EC) advising that it is revoking the refusal to grant a Marketing Authorization (MA) for Aplidin (plitidepsin) in multiple myeloma. 15 July 2024
Pharmaceutical
An inventory by KPMG has shown rising production of medicines in the Netherlands. 15 July 2024
Biotechnology
AbbVie on Friday revealed it has submitted applications for a new indication to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for Rinvoq (upadacitinib) 15mg, once daily for the treatment of adult patients with giant cell arteritis (GCA). 15 July 2024
Generics
India-based generic drugmaker Lupin Limited says it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for topiramate extended-release capsules. 15 July 2024
Biotechnology
M&A news last week featured US pharma major Eli Lilly announcing a $3.2 billion bid to acquire gastroenterology specialist Morphic. On the research front, US clinical-stage biotech HilleVax announced disappointing Phase IIb results with its norovirus vaccine HIL-214. Also, Dutch firm uniQure pleased investors with early--stage results for its investigational Huntington’s disease drug AMT-130, and US pharma gian
t Pfizer announced it is progressing its Parkinson’s disease candidate danuglipron. 14 July 2024
Pharmaceutical
Following its July 2024 meeting, the European Medicines Agency’s (EMA) safety committee (PRAC) has recommended new measures on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). 13 July 2024
Biosimilars
The mandate to conduct routine comparative clinical efficacy studies for biosimilar medicines, compounded by duplicative regional requirements, serves as a barrier to greater medicine access for patients, said the trade group International Generic and Biosimilar Medicines Association (IGBA). 13 July 2024
Biosimilars
South Korea’s Samsung Bioepis has released its Third Quarter 2024 Biosimilar Market Report, which includes the latest Average Sales Price (ASP) information of all biosimilars and reference products available in the US market. 12 July 2024
Biotechnology
Australian biotech Immutep has announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alfa (efti) in combination with Keytruda (pembrolizumab). 12 July 2024
Biotechnology
National Health Service (NHS) England has given approval to allow eligible patients access to Roche’s Ocrevus (ocrelizumab) subcutaneous injection for people with relapsing multiple sclerosis and primary progressive multiple sclerosis. 12 July 2024
Biotechnology
Canadian biotech Aspect Biosystems has received a $72.75 million investment from the Governments of Canada and British Columbia. 12 July 2024
Pharmaceutical
The global hormone replacement therapy (HRT) market, valued at $21 billion in 2023, is projected to grow to $38.8 billion by 2034. 12 July 2024
Biosimilars
India's Zydus Lifesciences has been barred by the Delhi High Court from selling its breast cancer drug, Sigrima, a biosimilar version of Roche's pertuzumab (brand name Perjeta). 12 July 2024
Biotechnology
The clinical trial landscape for chronic lymphocytic leukemia (CLL) shows a robust global effort to advance treatment options and understand the disease, according to a report. 12 July 2024
Biotechnology
The US Senate has unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150). 12 July 2024
Pharmaceutical
Shares of Texas, USA-based protein expert Salarius Pharmaceuticals fell more than 20% to $2.28 by close of trading on Thursday after the Food and Drug Administration (FDA) placed a study of the clinical-stage biopharmaceutical company's lead drug candidate on partial clinical hold. 12 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze